KalVista Pharmaceuticals (KALV) Total Current Liabilities (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Total Current Liabilities data on file, last reported at $38.4 million in Q3 2025.

• For the quarter ending Q3 2025, Total Current Liabilities rose 71.23% year-over-year to $38.4 million; the trailing twelve-month figure through Jul 2025 stood at $38.4 million (up 71.23% YoY), and the FY2025 full-year result was $45.2 million, up 98.04% from the prior year.
• Total Current Liabilities declined to $38.4 million in Q3 2025, from $45.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $45.2 million in Q2 2025 to a low of $6.5 million in Q1 2021.
• A 5-year average of $17.5 million and a median of $14.1 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities tumbled 33.23% in 2021 and jumped 98.04% in 2025, its largest moves.
• Tracing KALV's Total Current Liabilities over 5 years: stood at $10.1 million in 2021, then increased by 11.92% to $11.3 million in 2022, then surged by 56.81% to $17.8 million in 2023, then soared by 47.11% to $26.1 million in 2024, then jumped by 46.95% to $38.4 million in 2025.
• Business Quant data shows KALV's Total Current Liabilities at $38.4 million in Q3 2025, $45.2 million in Q2 2025, and $26.1 million in Q4 2024.